WIN Consortium in cancer personalized medicine Information

WIN: ACCOMPLISH TOGETHER WHAT ONE CANNOT ACHIEVE ALONE WIN IN NUMBERS: 18 countries over 4 continents 26 academic cancer centers - Access to patients from different populations 5 industries – Access to drugs and technologies 3 cancer patient organizations – The voice of the patients WIN MISSION: Significantly improve survival and quality of life of cancer patients across the world. WIN STRATEGY: (i) Perform proof of concept trials designed to explore novel strategies and tools aiming to: - Increase efficacy of Precision Oncology for advanced cancers and access to patients worldwide - Improve early diagnosis (ii) Share information about state of the art research across the world, the work of WIN members, WIN trials and more generally promoting the adoption of personalized cancer medicine globally through an annual symposium. Visit www.winsymposium.org WIN TRIALS: (i) WINTHER - trial results published in Nature Medicine https://doi.org/10.1038/s41591-019-0424-4 WINTHER heralds a new era for personalized medicine in oncology. WINTHER was the first trial to use transcriptome in addition to DNA investigations. Overall, the trial succeeded in matching personalized therapy to 35% of patients with advanced cancers. Patients with a good performance status and a high degree of matching had a significantly longer median overall survival of 25.8 months versus 4.5 months for others, independently of the number of previous therapies. Assessing RNA is an important adjunct to DNA profiling for determining precision treatments. (ii) SPRING_01 tritherapy trial (avelumab, palbociclib and axitinib) in first line of advanced/metastatic lung cancer. Phase I on going. Trial still enrolling at Avera Cancer Institute, USA, Vall d'Hebron (Spain), UC San Diego Moores Cancer Center, USA, Vall d’ Hebron Institute of Oncology, Spain, Centre Hospitalier de Luxembourg, Centre Léon Bérard, France. The trial will validate the SIMS algorithm for matching patients.